• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Repligen Corporation (Amendment)

    2/15/23 5:22:53 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGEN alert in real time by email
    SC 13G/A 1 ea173414-13ga5roy_replien.htm AMENDMENT NO. 5 TO SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G
    (Amendment No. 5)*

     

    Under the Securities Exchange Act of 1934

     

    Repligen Corporation

    (Name of Issuer)

     

    Common Stock, $.01 par value per share

    (Title of Class of Securities)

     

    759916109

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall not be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP NO. 759916109   Page 2 of 7 Pages

     

    1.

    NAMES OF REPORTING PERSON.

     

    Roy T. Eddleman Estate--Roy T. Eddleman Living Trust

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

    NUMBER OF
    SHARES

    BENEFICIALLY

    OWNED BY

    EACH
    REPORTING PERSON
    WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    2,705,689

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    2,705,689

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON.

     

    2,705,689

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.87%

    12.

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

     

    CUSIP NO. 759916109   Page 3 of 7 Pages

     

    1.

    NAMES OF REPORTING PERSON.

     

    Roy T. Eddleman Estate--Roy T. Eddleman Charitable Remainder Trust #1

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

    NUMBER OF
    SHARES

    BENEFICIALLY

    OWNED BY

    EACH
    REPORTING PERSON
    WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    509,318

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    509,318

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON.

     

    509,318

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.92%

    12.

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

     

    CUSIP NO. 759916109   Page 4 of 7 Pages

     

    1.

    NAMES OF REPORTING PERSON.

     

    Roy T. Eddleman Estate--Roy T. Eddleman Charitable Remainder Trust #2

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

    NUMBER OF
    SHARES

    BENEFICIALLY

    OWNED BY

    EACH
    REPORTING PERSON
    WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    284,993

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    284,993.

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON.

     

    284,993

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.51%

    12.

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

     

    CUSIP NO. 759916109   Page 5 of 7 Pages

     

    Item 1(a). Name of issuer: Repligen Corporation.

     

    Item 1(b). Address of issuer’s principal executive offices: 41 Seyon Street, Waltham, Massachusetts 02453

     

    Item 2(a). Name of person filing:

     

    (i)Roy T. Eddleman Living Trust

     

    (ii)Roy T. Eddleman Charitable Remainder Trust #1

     

    (iii)Roy T. Eddleman Charitable Remainder Trust #2

     

    Item 2(b). Address of principal business office, or, if none, residence: c/o TroyGould PC, 1801 Century Park East, 16th Floor, Los Angeles, California 90067, Attention: Istvan Benko.

     

    Item 2(c). Citizenship: Each reporting person was formed under the laws of the United States.

     

    Item 2(d). Title of class of securities: Common stock, $.01 par value per share, of the Issuer.

     

    Item 2(e). CUSIP No.: 759916109

     

    Item 3.If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a–8);

     

    (e)¨ An investment adviser in accordance with §240.13d–1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d–1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with §240.13d–1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a–3);

     

    (j)¨ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J); and

     

    (k)¨ Group, in accordance with §240.13d–1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution.

     

     

     

     

    CUSIP NO. 759916109   Page 6 of 7 Pages

     

    Item 4. Ownership.

     

    Until his death on June 11, 2022, Roy T. Eddleman was the sole trustee of each of the reporting persons, and as such had investment and voting control over the shares covered by this Schedule (the “Shares”). This Amendment is being filed to reflect the fact that Mr. Eddleman has died and that Nereyda Rubio and Anis Garci have replaced Mr. Eddleman as the co-trustees of each reporting person. As co-trustees, each co-trustee has investment and voting control over the Shares and may be deemed to have shared voting power and shared investment power with respect to all such Shares. The co-trustees disclaim beneficial ownership of each reporting persons’ Shares except to the extent of his/her pecuniary interest therein. Mr. Eddleman’s estate is still in administration in preparation of the required distribution of the Shares.

     

    The percentage ownership information is calculated based upon 55,519,646 shares of common stock of the Issuer issued and outstanding as of September 30, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 1, 2022.

     

    (a)See Item 9 of the cover page.

     

    (b)See Item 9 of the cover page.

     

    (c)Number of shares as to which the reporting persons have:

     

    (i)Sole power to vote or direct the vote: 0.

     

    (ii)Shared power to vote or direct the vote: 3,500,000.

     

    (iii)Sole power to dispose or direct the disposition: 0.

     

    (iv)Shared power to dispose or direct the disposition: 3,500,000.

     

    Item 5.Ownership of Five Percent or Less of a Class. If this Schedule is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person. Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group. Not Applicable.

     

    Item 9.Notice of Dissolution of Group. Not Applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP NO. 759916109   Page 7 of 7 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: February 15, 2023
       
      Roy T. Eddleman Living Trust
       
      /S/ Nereyda Rubio
      Name: Nereyda Rubio
      Its: Co-Trustee
       
      /S/ Anis Garci
      Name: Anis Garci
      Its: Co-Trustee
       
      Roy T. Eddleman Charitable Remainder Trust #1
       
      /S/ Nereyda Rubio
      Name: Nereyda Rubio
      Its: Co-Trustee
       
      /S/ Anis Garci
      Name: Anis Garci
      Its: Co-Trustee
       
      Roy T. Eddleman Charitable Remainder Trust #2
       
      /S/ Nereyda Rubio
      Name: Nereyda Rubio
      Its: Co-Trustee
       
      /S/ Anis Garci
      Name: Anis Garci
      Its: Co-Trustee

     

     

     

     

     

    Get the next $RGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RGEN

    DatePrice TargetRatingAnalyst
    6/24/2025$150.00Overweight
    Barclays
    4/29/2025$160.00Peer Perform → Outperform
    Wolfe Research
    3/18/2025$155.00In-line
    Evercore ISI
    2/10/2025$200.00Buy
    TD Cowen
    12/17/2024$165.00Hold
    Canaccord Genuity
    11/14/2024Peer Perform
    Wolfe Research
    8/28/2024$180.00Overweight
    Wells Fargo
    6/26/2024$180.00 → $155.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $RGEN
    SEC Filings

    See more
    • Repligen Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - REPLIGEN CORP (0000730272) (Filer)

      5/15/25 4:15:37 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Repligen Corporation

      10-Q - REPLIGEN CORP (0000730272) (Filer)

      4/29/25 4:17:25 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - REPLIGEN CORP (0000730272) (Filer)

      4/29/25 7:32:59 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays initiated coverage on Repligen with a new price target

      Barclays initiated coverage of Repligen with a rating of Overweight and set a new price target of $150.00

      6/24/25 8:09:38 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Repligen from Peer Perform to Outperform and set a new price target of $160.00

      4/29/25 2:20:14 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Repligen with a new price target

      Evercore ISI initiated coverage of Repligen with a rating of In-line and set a new price target of $155.00

      3/18/25 7:55:20 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • 908 Devices Appoints Christopher D. Brown to its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

      6/16/25 8:00:00 AM ET
      $AAPL
      $MASS
      $RGEN
      $TMO
      Computer Manufacturing
      Technology
      Industrial Machinery/Components
      Industrials
    • Repligen Appoints Jacob Johnson As Vice President Investor Relations

      WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team's engagement with the investment community, reporting to the company's Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. Mr. Garland commented, "Jacob is a terrific addition to the Repligen team, bringing a broad understanding of the bioprocessing tools space, the markets we serve and the growth driver

      4/8/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

      BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is

      12/16/24 8:11:00 AM ET
      $BLFS
      $RGEN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)